LLY vs JNJ — Key Metrics

Metric LLY (ELI LILLY & CO) JNJ (JOHNSON & JOHNSON)
Price1382.75272.7
Market Cap1.3 Trillion656.47 Billion
P/E (TTM)44.8240.82
P/B (Quarterly)32.097.611
P/S (TTM)15.046.61
Net Profit Margin (TTM)31.916.2
Gross Margin (TTM)83.667.6
ROE (TTM)83.619.6
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

ELI LILLY & CO
vs
 
JOHNSON & JOHNSON
 
ELI LILLY & CO
vs
 
JOHNSON & JOHNSON
Performance Comparison
AI Model Recommendation
LLY · ELI LILLY & CO

Underperform

-30
UnderperformOutperform
JNJ · JOHNSON & JOHNSON

Outperform

21
UnderperformOutperform
Recommendation Summary

Stock LLY is projected to underperform the market, stock JNJ is projected to outperform the market. Upfront Recommendation: JNJ.

Financial Metrics
Prices delayed ~15 min
LLY Metrics JNJ
$1,382.75 Price $272.70
— Market Capitalization —
44.82 Price to Earnings Ratio 40.82
15.04 Price to Sales 6.61
66.16 Price to FCF Ratio 31.88
17.99 Price to Gross Profit 9.78
84.59 Price to R&D 40.82
19.93 Price to Current Assets 11.65

LLY vs JNJ at a glance

ELI Lilly & CO (LLY) and Johnson & Johnson (JNJ) are both Drug Manufacturers - General companies in the Healthcare sector. LLY is the larger, at $1.3 trillion in market value against $656.5 billion for JNJ, about 2.0 times the size.

On trailing-twelve-month figures, LLY trades at 44.8 times trailing earnings and JNJ at 40.8; net profit margins are 31.9% and 16.2%.

The Upfront Investment model currently rates LLY Underperform and JNJ Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.